Soumya D. Chakravarty

2.5k total citations
88 papers, 1.7k citations indexed

About

Soumya D. Chakravarty is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Soumya D. Chakravarty has authored 88 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Rheumatology, 57 papers in Immunology and 39 papers in Hematology. Recurrent topics in Soumya D. Chakravarty's work include Spondyloarthritis Studies and Treatments (55 papers), Psoriasis: Treatment and Pathogenesis (54 papers) and Autoimmune and Inflammatory Disorders Research (39 papers). Soumya D. Chakravarty is often cited by papers focused on Spondyloarthritis Studies and Treatments (55 papers), Psoriasis: Treatment and Pathogenesis (54 papers) and Autoimmune and Inflammatory Disorders Research (39 papers). Soumya D. Chakravarty collaborates with scholars based in United States, United Kingdom and Canada. Soumya D. Chakravarty's co-authors include Lionel B. Ivashkiv, Xiaoyu Hu, JoAnne L. Flynn, John Chan, Ming Chih Tsai, Guofeng Zhu, Jiayong Xu, Kathryn E. Tanaka, JoAnn M. Tufariello and Cameron J. Koch and has published in prestigious journals such as The Journal of Immunology, Infection and Immunity and Immunological Reviews.

In The Last Decade

Soumya D. Chakravarty

84 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Soumya D. Chakravarty United States	20	1.0k	702	415	400	389	88	1.7k
Furen Zhang China	19	445 0.4×	262 0.4×	307 0.7×	88 0.2×	290 0.7×	118	1.5k
Marek Karczewski Poland	12	878 0.9×	257 0.4×	82 0.2×	180 0.5×	278 0.7×	48	1.6k
Soheil Tavakolpour Iran	21	197 0.2×	441 0.6×	393 0.9×	150 0.4×	190 0.5×	86	1.5k
Prapaporn Pisitkun Thailand	21	1.9k 1.9×	725 1.0×	222 0.5×	73 0.2×	195 0.5×	51	2.4k
C. Leonardi United States	26	1.6k 1.5×	344 0.5×	99 0.2×	221 0.6×	309 0.8×	57	2.1k
F. Ameglio Italy	24	733 0.7×	279 0.4×	184 0.4×	117 0.3×	246 0.6×	65	1.4k
J. Sieper Germany	18	897 0.9×	1.7k 2.4×	61 0.1×	611 1.5×	123 0.3×	84	2.3k
Silvia Helou Argentina	10	1.3k 1.3×	332 0.5×	218 0.5×	212 0.5×	326 0.8×	16	1.7k
Helen Benham Australia	13	787 0.8×	603 0.9×	62 0.1×	266 0.7×	93 0.2×	31	1.3k
Chihiro Terai Japan	20	462 0.5×	343 0.5×	184 0.4×	150 0.4×	258 0.7×	83	1.6k

Countries citing papers authored by Soumya D. Chakravarty

Since Specialization

Citations

This map shows the geographic impact of Soumya D. Chakravarty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soumya D. Chakravarty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soumya D. Chakravarty more than expected).

Fields of papers citing papers by Soumya D. Chakravarty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soumya D. Chakravarty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soumya D. Chakravarty. The network helps show where Soumya D. Chakravarty may publish in the future.

Co-authorship network of co-authors of Soumya D. Chakravarty

This figure shows the co-authorship network connecting the top 25 collaborators of Soumya D. Chakravarty. A scholar is included among the top collaborators of Soumya D. Chakravarty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soumya D. Chakravarty. Soumya D. Chakravarty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ogdie, Alexis, Soumya M. Reddy, M. Elaine Husni, et al.. (2025). Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials. 26(1). 96–96. 1 indexed citations

Mease, Philip J., Christopher T. Ritchlin, Laura C. Coates, et al.. (2025). Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study. Annals of the Rheumatic Diseases. 84(12). 1983–1994.

Mease, Philip J., Shannon Ferrante, Natalie J. Shiff, et al.. (2024). Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors. Advances in Therapy. 42(2). 734–751. 1 indexed citations

Ritchlin, Christopher T., Philip J. Mease, Wolf‐Henning Boehncke, et al.. (2024). Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical Rheumatology. 43(8). 2551–2563. 1 indexed citations

Orbai, Ana‐Maria, et al.. (2023). Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis. Dermatology and Therapy. 13(11). 2859–2868. 4 indexed citations

Schett, Georg, Sheng Gao, Soumya D. Chakravarty, et al.. (2023). Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. Arthritis Research & Therapy. 25(1). 150–150. 6 indexed citations

Kavanaugh, Arthur, Xenofon Baraliakos, Sheng Gao, et al.. (2023). Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials. Advances in Therapy. 40(5). 2439–2456. 11 indexed citations

Mease, Philip J., Alice B. Gottlieb, Alexis Ogdie, et al.. (2023). Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clinical Rheumatology. 43(1). 241–249. 1 indexed citations

McGonagle, Dennis, Iain B. McInnes, Atul Deodhar, et al.. (2023). Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR Open Rheumatology. 5(4). 227–240. 4 indexed citations

10.

Mease, Philip J., Dafna D. Gladman, Denis Poddubnyy, et al.. (2023). Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study. Rheumatology and Therapy. 10(6). 1637–1653. 11 indexed citations

11.

Gossec, Laure, Elke Theander, Soumya D. Chakravarty, et al.. (2023). Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study. Arthritis Research & Therapy. 25(1). 100–100. 2 indexed citations

12.

Strober, Bruce, Laura C. Coates, Mark Lebwohl, et al.. (2023). Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug Safety. 47(1). 39–57. 31 indexed citations

13.

Lee, Jong Bong, Yijun Fan, Chuanpu Hu, et al.. (2022). Population Pharmacokinetic and Exposure–Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis. Clinical Therapeutics. 44(3). 457–464.e2. 1 indexed citations

14.

Gossec, Laure, Jessica A. Walsh, Kaleb Michaud, et al.. (2022). Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. The Journal of Rheumatology. 49(11). jrheum.211288–jrheum.211288. 11 indexed citations

15.

Mease, Philip J., Soumya D. Chakravarty, Robert R. McLean, et al.. (2022). Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen‐B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatology. 4(5). 447–456. 6 indexed citations

16.

Mease, Philip J., A.B. Gottlieb, Iain B. McInnes, et al.. (2022). POS1035 LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23p19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 81. 831–832. 1 indexed citations

17.

Ritchlin, Christopher T., Philip Helliwell, Wolf‐Henning Boehncke, et al.. (2021). Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced. RMD Open. 7(1). e001457–e001457. 50 indexed citations

18.

Mease, Philip J., Iain B. McInnes, Lai‐Shan Tam, et al.. (2021). Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Lara D. Veeken. 60(5). 2109–2121. 42 indexed citations

19.

Deodhar, Atul, Soumya D. Chakravarty, Chris Cameron, et al.. (2020). A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis. Clinical Rheumatology. 39(8). 2307–2315. 20 indexed citations

20.

Ritchlin, Christopher T., Mona Ståhle, Yves Poulin, et al.. (2019). Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. BMC Rheumatology. 3(1). 52–52. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact